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Transforming growth factor (TGF)-b1 is a multifunctional cytokine that plays important roles in regulating cell growth and
differentiation in many biological systems. In this study, we found that gastric tissue-derived Epstein–Barr virus (EBV)-infected
epithelial cell lines GT38 and GT39 had resistance to TGF-b1-mediated growth inhibition and apoptosis compared to a
TGF-b1-susceptible gastric carcinoma cell line HSC-39. However, TGF-b1 partially induced EBV reactivation in GT38 and
GT39 cells, as shown by the induction of EBV immediate-early BZLF1 RNA and its protein product ZEBRA and early antigen-D.
The expressions of TGF-b receptor I and II were detected in GT38 and GT39 cells by Northern and Western blot analyses.
Both cell lines spontaneously produced the TGF-b1, which was sufficient for inhibiting cell growth of HSC-39 cells. Taken
together, these data suggest that TGF-b1 may be a key factor for EBV reactivation and selective growth of EBV-infected
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INTRODUCTION
Epstein–Barr virus (EBV) ubiquitously infects the ma-
jority of humans and is the causative agent of infectious
mononucleosis. EBV infection has been closely linked to
various epithelioid and lymphoid malignancies (Rickin-
son and Kieff, 1996). Many studies have also indicated a
relationship between EBV and gastric carcinoma (Shi-
bata and Weiss, 1992; Fukayama et al., 1994; Sugiura et
al., 1996). Analysis of the EBV DNA, which shows clonal-
ity from gastric carcinoma cells, indicated that tumors
arose from a single EBV-infected cell, thus suggesting
that EBV infection had occurred in the very early stage of
tumor development (Imai et al., 1994). Furthermore, ele-
vated EBV antibody titers to viral lytic antigens in pa-
tients’ sera with EBV-associated gastric adenocarcinoma
presumably reflected EBV reactivation in the gastric car-
cinoma cells (Imai et al., 1994; Levine et al., 1995). Little,
however, is known about the mechanisms for clonal
expansion of EBV-infected gastric carcinoma cells and
reactivation of viral latency in the EBV-positive epithelial
cells.
Transforming growth factor (TGF)-b superfamily mem-
ers, including activin, bone morphogenetic protein, and
GF-b, play important regulatory roles in cell growth,
1 To whom correspondence and reprint requests should be ad-
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109morphogenesis, cell differentiation, and apoptosis
(Sporn and Roberts, 1992; Massague, 1998). The effects
of TGF-b on cell growth in vitro can be positive or neg-
tive depending on cell types, culture conditions, and
resence of other growth factors. In most cells of epi-
helial origin, TGF-b is a potent growth inhibitor (Sporn
nd Roberts, 1992).
Gastric carcinoma cells express a number of growth
actors, gastrointestinal hormones, and cytokines that
ay enhance the growth of these tumor cells through
otential autocrine, paracrine, and juxtacrine pathways
Tahara et al., 1990). Among them, elevated levels of
GF-b have been reported in patients with human gastric
ancer (Mizoi et al., 1993; Naef et al., 1997).
In the relationship of TGF-b and EBV, TGF-b induces
iral reactivation in EBV-infected B cells (di Renzo et al.,
994). Besides, EBV abrogates the TGF-b-mediated
rowth inhibition in human B cells (Arvanitakis et al.,
995). These observations lead us to postulate that
GF-b may be an important factor to induce certain
virological and immunological findings in EBV-associ-
ated gastric carcinoma. We hypothesize that TGF-b may
ontrol the growth and EBV reactivation of EBV-infected
pithelial cells. Although the interaction between EBV
nd lymphoid cells has been studied extensively, in vitro
studies of EBV in epithelial cells has been hampered by
the lack of an experimental cell system, which is sus-
ceptible to EBV. To explore our hypothesis, we examined
the effect of TGF-b1 on EBV-infected epithelial cell lines
0042-6822/01 $35.00
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1 DA ETGT38 and GT39 derived from gastric tissues (Tajima et
al., 1998). These cell lines were established from non-
cancerous portions of the gastric carcinoma of two pa-
tients and had spontaneous EBV reactivation in small
numbers of cells. The EBV latency was referred to as
type III, which expresses EBNA1, EBNA2, and LMP1
(Takasaka et al., 1998; Murakami et al., 2000). These cell
lines formed colonies in soft agar (Kanamori et al., 2000)
and tumors in SCID mice (Murakami et al., 2000).
In this study, we found that GT38 and GT39 cell lines
resisted TGF-b1-mediated growth inhibition and apopto-
sis, while latent EBV in the cells was partially reactivated
by TGF-b1. We analyzed the expression of TGF-b recep-
tors (Rs) and TGF-b1-mediated signals in these cell lines
nd found that these cell lines spontaneously produced
GF-b1, which may modulate the cell growth and EBV
reactivation.
RESULTS
Effect of TGF-b1 on the cell growth and apoptosis
EBV-positive and -negative B cells exhibit a differential
esponse to TGF-b. EBV-negative B cells are sensitive to
GF-b-mediated growth inhibition, whereas EBV-positive
B cells lose that sensitivity (Arvanitakis et al., 1995). To
characterize the effect of TGF-b1 on growth of GT38 and
T39 cells, we measured the TGF-b1-mediated growth
nhibition in parallel to HSC-39 cells in which growth
nhibition and apoptosis were induced by TGF-b1
(Yanagihara and Tsumuraya, 1992). By the 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT)
assay, we observed differential sensitivity to TGF-b1 in
rowth of these cell lines (Fig. 1A). Growth of HSC-39
ells was inhibited with TGF-b1 in a dose-dependent
anner. It was inhibited at 0.5 ng/ml of TGF-b1 partly and
almost completely at 5 ng/ml or higher concentrations.
On the other hand, the growth of GT38 and GT39 cells
was not or little inhibited at those concentrations of
TGF-b1. We analyzed whether TGF-b1 induces apoptosis
in these cell lines by a DNA fragmentation test (Fig. 1B).
DNA fragmentation was induced in HSC-39 cells by
TGF-b1. In contrast, DNA fragmentation was not ob-
served in GT38 and GT39 cells.
Expression of TGF-b Rs I and II
Lack of expression of TGF-b Rs has been reported in
astric cancer cell lines (Park et al., 1994; Yamamoto et
l., 1996). We investigated the expression of TGF-b Rs I
nd II in GT38, GT39, a gastric cancer cell line MKN1, and
SC-39 cells by Northern and Western blot analyses.
xpression of mRNAs of TGF-b Rs I (5.2 kb) and II (5.5 kb)
were detected in all cell lines to similar levels (Fig. 2A).
10 FUKUExpression of proteins of TGF-b Rs I and II were also
detected in all cell lines (Fig. 2B). iEffect of TGF-b1 on EBV reactivation
TGF-b1 induces EBV reactivation in B cell lines (di
Renzo et al., 1994). We studied the effect of TGF-b1 on
FIG. 1. Effect of TGF-b1 on the cell growth and apoptosis in HSC-39,
GT38, and GT39 cells. (A) Cells were seeded at 5 3 103 cells/100 ml per
ell and incubated for 24 h and then were cultured for 72 h with various
oncentrations of TGF-b1. Cell growth was measured by MTT assay.
Results are the means and standard deviations for five experiments. (B)
Cells (1 3 106 cells/ml) were cultured with (1) or without (2) TGF-b1
10 ng/ml) for 24 h at 37°C. DNA was isolated from the cells, subjected
o the agarose gel electrophoresis, and visualized with ethidium bro-
ide. Anti-IgM-treated Ramos cells were used as the positive control
or the DNA fragmentation (lane C).
AL.EBV reactivation in GT38 and GT39 cells (Fig. 3). TGF-b1
nduced the EBV immediate-early gene BZLF1, protein
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ATIONZEBRA (Countryman et al., 1987; Kenney et al., 1989). We
analyzed the time course of the TGF-b1-dependent in-
uction of BZLF1 mRNA, ZEBRA, and EA-D, markers of
BV reactivation in GT38 cells (Fig. 3A). The levels of
ZLF1 and BRLF1 expression increased at 8 h and
eached a maximal level at 48 h. The levels of ZEBRA
xpression increased at 24 h and reached a maximal
evel at 48 h. The size of ZEBRA in Akata cells is smaller
FIG. 2. Expression of TGF-b Rs I and II in GT38, GT39, MKN1, and
SC-39 cells. (A) Thirty micrograms of total RNA was subjected to the
orthern blotting. GAPDH mRNA was hybridized to show that compa-
able amounts of mRNA had been loaded in each lane (left). The
utoradiographs for TGF-b R I, II, and GAPDH mRNAs were analyzed by
aser densitometry and the RNA levels of TGF-b Rs were normalized to
the corresponding GAPDH signals (right). (B) Thirty micrograms of
protein from the cells was separated electrophoretically, blotted onto
membranes, and then immunoreacted with anti-human TGF-b Rs I and
II Abs. The positions of the TGF-b Rs I (53 kDa) and II (70 kDa) bands
are indicated by an arrow (left). The autoradiographs for TGF-b Rs I and
II band intensities were analyzed by laser densitometry (right).
EBV REACTIVhan that of prototypic virus strain B95-8 (Packham et al.,
993) and than those of GT38 and GT39 cells (Takasaka
Z
at al., 1998). The levels of EA-D expression also in-
reased by 48 h and reached a higher level at 72 h. We
ested the effective doses of TGF-b1 for the EBV reacti-
vation in GT38 cells (Fig. 3B). ZEBRA and EA-D were
induced at 5 ng/ml and greater concentrations of TGF-b1.
EBRA and EA-D inductions were observed similarly in
T39 (data not shown) cells.
GF-b1 Rs of GT38 cells mediate TGF-b1 signals
To characterize TGF-b1-mediated signal transduction
in GT38 cells, we tested for expression of plasminogen
activator inhibitor-1 (PAI-1) and junB, which are up-regu-
FIG. 3. Effect of TGF-b1 on EBV reactivation in GT38 cells. (A) Time
course for EBV reactivation in TGF-b1-treated GT38 cells. GT38 cells
ere cultured with or without TGF-b1 (10 ng/ml). Total RNA was ex-
tracted from GT38 cells at 0, 4, 8, 12, 24, and 48 h after treatment with
TGF-b1. Northern hybridization was performed using cDNA probes for
BZLF1 and GAPDH. The expression of ZEBRA and EA-D was analyzed
by Western blot analysis. Forty micrograms of protein from the cells at
the indicated times after treatment with TGF-b1 (10ng/ml) was sepa-
rated electrophoretically, blotted onto membranes, and then immuno-
reacted with anti-ZEBRA and anti-EA-D Abs. Anti-IgG-treated Akata
cells (lane C) and 12-O-tetradecanoylphorbol-13-acetate-treated GT38
cells for 72 h were used as the positive controls for ZEBRA and EA-D,
respectively. (B) Dose response of TGF-b1 on EBV reactivation. GT38
cells were treated with various concentrations of TGF-b1 for 72 h.
111BY TGF-b1EBRA and EA-D were detected in the cells by immunoblotting with
nti-ZEBRA and anti-EA-D Abs as shown in (A).
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TGF-b1 rapidly induced PAI-1 and junB expression more
than sixfold and twofold, respectively, in HSC-39 cells to
the untreated cells (Fig. 4A). In contrast, TGF-b1 induced
little PAI-1 expression; however, JunB was induced rap-
idly and strongly in GT38 cells (Fig. 4B).
GT38 and GT39 cells express TGF-b1 mRNA
TGF-bs are overexpressed in gastric carcinoma tis-
sues and derived cell lines (Mizoi et al., 1993; Naef et al.,
1997; Yamamoto et al., 1996). We examined expression of
GF-b1 mRNA by Northern blot analysis in GT38, GT39,
HSC-39, in additional gastric cancer cell lines MKN1 and
NUGC3, and in an EBV-positive gastric carcinoma spec-
imen (GC). TGF-b1 mRNA with about 2.5 kb was detected
n the all cell lines and the gastric carcinoma tissue (Fig.
A). The TGF-b1 mRNA levels of GT38, GT39, and MKN1
ells were slightly greater than in the other cell lines and
he carcinoma tissue (Fig. 5B).
T38 and GT39 cells release biologically active
GF-b1
FIG. 4. TGF-b1 induction of PAI-1 and junB expression in HSC-39 (A)
and GT38 (B) cells. Cells were cultured with fresh medium for 24 h at
37°C and then exposed to TGF-b1 (10 ng/ml). The cells were harvested
at various times. Northern hybridization was performed on the same
membrane using cDNA probes for PAI-1, junB, and GAPDH, respec-
tively (left). Activation (fold induction) of the PAI-1 and junB expressions
in TGF-b1-treated vs the control cells was evaluated with laser densi-
tometry (right). Ratios of the optical densities between PAI-1/junB and
the corresponding GAPDH signals were calculated and the RNA levels
of PAI-1/junB were normalized.
12 FUKUWe analyzed whether GT38 and GT39 cells produce
TGF-b1 in the supernatants using the fluorometric sand-
n
dwich ELISA and the growth inhibition assay. These tests
enable TGF-b1 to be characterized as an active form on
irect assay of the supernatant, or as both latent and
ctive forms (total TGF-b1), following heat treatment for
10 min at 80°C (Brown et al., 1990). Heat treatment
eleases the TGF-b1 from a carrier protein.
The active and total TGF-b1 were assayed in super-
atants from GT38 and GT39 cells by ELISA (Table 1).
he TGF-b1 in supernatants from GT38 and GT39 cells
were detected with similar levels.
The biological activity of TGF-b1 was examined by a
growth inhibition assay using the HSC-39 cells, a sensi-
tive cell line to TGF-b1. As expected, the supernatants
from GT38 or GT39 cells inhibited the growth of HSC-39
cells (Figs. 6A and 6B). We demonstrated that the growth
FIG. 5. Expression of the TGF-b1 mRNA in a gastric carcinoma tissue
(GC), GT38, GT39, HSC-39, MKN1, and NUGC3 cells. (A) Thirty micro-
grams of total RNA from the cells was subjected to Northern blotting for
TGF-b1. GAPDH was used as the internal control. (B) The autoradio-
graph (A) was analyzed with a laser densitometry. Ratios of the optical
densities between TGF-b1 and the corresponding GAPDH signals
were calculated and the RNA levels of TGF-b1 were normalized.
TABLE 1
Amount of TGF-b1 in the Culture Supernatants
from GT38 and GT39 Cells
Cells Active (ng/ml) Total (ng/ml)
T38 0.37 6 0.09 0.62 6 0.12
T39 0.32 6 0.05 0.54 6 0.15
Note. The cells (1 3 106 cells/ml) were cultured for 24 h, and the
amounts of active and total TGF-b1 were assayed in the culture super-
AL.atants by ELISA. Values are expressed as the mean 6 standard
eviation. Data represent the means of five experiments.
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ted coninhibition was due to active TGF-b1 in the supernatants
by blocking the growth inhibition by anti-TGF-b1 antibody
Ab). The growth-inhibitory activity in the supernatants
as reduced partially by the anti-TGF-b1 Ab. The growth-
nhibitory activity of heated supernatants was observed
t more higher levels than those of the unheated super-
atants and they were reduced similarly with anti-TGF-b1
Ab. The supernatants from GT38 or GT39 cells slightly
inhibited the growth of GT38 cells; however, the growth
inhibition with the fresh and heated supernatants was
not reduced with anti-TGF-b1 Ab (Fig. 6C). To confirm the
growth inhibition by TGF-b1, we analyzed in more detail
FIG. 6. Detection of TGF-b1 activity in the supernatants from GT38 o
SC-39 cells. HSC-39 (5 3 103 cells/100 ml) cells were cultured in the s
ntreated (open bar) or treated at 80°C for 10 min (shaded bar). The s
he cell growth was measured by MTT assay and the inhibition of cell
ar). (C) Effect of the supernatants from GT38 or GT39 cells on the ce
s shown in (A) and (B). (D) The dose response of anti-TGF-b1 Ab on
to HSC-39 cells. The cells were cultured and the growth was determin
for five experiments. * P , 0.05, **P , 0.01 compared with the untrea
EBV REACTIVhe effect by the anti-TGF-b1 Ab in the GT38 supernatant.
Anti-TGF-b1 Ab blocked the growth-inhibition in a dose-dependent fashion (Fig. 6D). The Ab also blocked the
growth inhibition of the heated supernatant.
We further analyzed whether the supernatant from
GT38 cells induces apoptosis in HSC-39 cells by flow
cytometry (Fig. 7). Apoptotic cells contain less DNA,
which is due to DNA fragmentation than the cells in
G0/G1 phase (Fukuda et al., 1995). The proportion (,G1)
f apoptotic cells was 6.5% in the control HSC-39 cells.
he proportion increased in the cells incubated with
GF-b1 or with supernatant from GT38 cells to 18.1 or
14.7%, respectively. The proportions reduced to 7.9 or
10.2%, respectively, in the cells cultured with TGF-b1 or
cells. TGF-b1 activity was assessed by the growth inhibition using the
tants from GT38 (A) or GT39 (B) cells for 72 h. The supernatants were
tants were treated with (1) or without (2) anti-TGF-b1 Ab (100 ng/ml).
was determined to the cells cultured with fresh medium (lane C; open
th of GT38 cells. The cells were cultured and growth was determined
cking the growth-inhibitory activity of the supernatant from GT38 cells
shown in (A) and (B). Results are the means and standard deviations
trol group analyzed by the unpaired t test.
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We also observed that the supernatants from GT38
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DA ETand GT39 cells up-regulated the expressions of PAI-1
and junB in HSC-39 cells (data not shown), as demon-
strated by TGF-b1 in Fig. 4.
DISCUSSION
We have provided new evidence that EBV-infected
pithelial cell lines GT38 and GT39 are resistant to
GF-b1 and yet produce biologically active TGF-b1.
First, we demonstrated that GT38 and GT39 cells, in
contrast to HSC-39 cells (Yanagihara and Tsumuraya,
1992), are resistant to TGF-b1-mediated growth inhibition
nd apoptosis. There are a number of potential mecha-
isms for this lack of TGF-b responsiveness, i.e., muta-
tional inactivation or deletion of TGF-b receptors or
SMAD proteins which are signaling molecules for
TGF-b1 (Heldin et al., 1997; Massague, 1998). Lost sen-
itivity to TGF-b is common in several kinds of carci-
FIG. 7. Supernatant from GT38 cells induces apoptosis in HSC-39
cells. HSC-39 (5 3 105 cells/ml) cells were cultured in medium (A),
TGF-b1- (1.5 ng/ml) containing medium (B), the supernatant from GT38
cells (C), anti-TGF-b1 Ab- (1 mg/ml) treated TGF-b1 (1.5 ng/ml) contain-
ing medium (D) or anti-TGF-b1 Ab- (1 mg/ml) treated supernatant (E) for
48 h. The cells were fixed with 70% ethanol, stained with propidium
iodide, and analyzed by flow cytometry. The DNA content of the non-
gated population was expressed as the histogram of propidium iodide
fluorescence intensity. The percentage of apoptotic cells (,G1; defined
by horizontal bars) is denoted in each histogram.
114 FUKUnoma. Changes in expression of the TGF-b R II have
een found in gastric (Park et al., 1994), colorectal
g
TMarkowitz et al., 1995; Wang et al., 1995), and breast
(Sun et al., 1994) carcinomas due to genetic changes in
TGF-b R II. Escape from TGF-b sensitivity has been
reported to result from inactivation of the TGF-b R I gene
in a gastric carcinoma cell line (Kim et al., 1996). De-
reased expression of TGF-b Rs I and II have been
observed in gastric and thyroid carcinomas (Ito et al.,
1992; Lazzereschi et al., 1997). We demonstrated the
expression of mRNAs and proteins of TGF-b Rs I and II
in GT38 and GT39 cells (Fig. 2). These results suggest
that the resistance of GT38 and GT39 cells to TGF-b1-
mediated growth inhibition and apoptosis is not due to
the loss of TGF-b Rs.
Second, we found that TGF-b1 induced EBV reactiva-
tion in GT38 and GT39 cells that were derived from
gastric tissues. TGF-b induces the viral productive cycle
in Burkitt lymphoma cell lines and marmoset B lympho-
cytes immortalized with EBV (di Renzo et al., 1994; Witt-
mann et al., 1982). GT38 and GT39 cells had about 1%
EA-positive cells before treatment with TGF-b1 and the
EA-positive cells increased to about 8% at 72 h after
TGF-b1 treatment (data not shown). The level of EBV
reactivation with TGF-b1 was similar to that with 12-O-
etradecanoylphorbol-13-acetate (TPA), which also in-
uced EBV reactivation in these cells (Fig. 3; Kanamori et
l., 2000). These results indicated that EBV was reacti-
ated in part of GT38 and GT39 cells by TGF-b1, although
these cells were resistant to TGF-b1-mediated growth
inhibition and apoptosis (Figs. 1, 3).
Third, we analyzed the TGF-b1 signaling pathways in
SC-39 and GT38 cells, finding different activation pat-
erns of the TGF-b1-mediated signaling molecules.
TGF-b1 clearly induced PAI-1 and junB expression in
HSC-39 cells; however, it induced junB, but little PAI-1 in
GT38 cells (Fig. 4). These results suggest that EBV in
GT38 and GT39 cells is likely to be reactivated via the
junB pathway induced by TGF-b1.
Fourth, we detected TGF-b1 mRNA in GT38 and GT39
ells and the biologically active TGF-b1 in the superna-
ants (Figs. 5–7; Table 1). Using a specific antibody to
GF-b1, we showed clearly that a part of growth inhibi-
tion and induction of apoptosis in HSC-39 cells were due
to TGF-b1 in the supernatants from GT38 and GT39 cells.
he TGF-b1 level in the supernatants from GT38 cells
nhibited the growth of HSC-39 cells, but not the growth
f GT38 cells (Table 1; Fig. 6). These data were consis-
ent with the result that GT38 and GT39 cells are resis-
ant to the exogenous TGF-b1-mediated growth inhibi-
tion and apoptosis (Fig. 1).
TGF-b1 produced by GT38 or GT39 cells does not
inhibit the growth of those cells but can inhibit growth of
other TGF-b1-susceptible cells. One can hypothesize
that EBV-infected cells have resistance to TGF-b1-medi-
ted growth inhibition, and therefore can selectively out-
AL.row in the neighboring cells which are susceptible for
GF-b1 produced by EBV-infected cells. Such EBV-in-
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EBV-infected cells as observed in EBV-associated gas-
tric carcinoma (Imai et al., 1994). However, we do not
have the direct evidence that the resistance of GT38 and
GT39 cells to TGF-b1 is due to by EBV infection itself.
Furthermore, the EBV latency of type in these cell lines
(Tajima et al., 1998; Takasaka et al., 1998; Murakami et
l., 2000) does not fit in the latency I observed in most
BV-associated gastric carcinomas (Imai et al., 1994,
ugiura et al., 1996). It remains to be studied that EBV
nfection induces the loss of TGF-b responsiveness in
epithelial cells.
Induction of TGF-b1 has been proposed to play a role
in the immunosuppression observed during human T-
lymphotropic virus type 1 and cytomegalovirus infections
(Kim et al., 1990; Michelson et al., 1994). Induction of
TGF-b1 could be a common mechanism used by human
viruses to down-regulate host immune responses.
In summary, we have demonstrated that the human
gastric tissue-derived epithelial cell lines GT38 and GT39
are resistant to the growth inhibition and apoptosis but
are sensitive to EBV reactivation by TGF-b1. They pro-
duce TGF-b1, which inhibits TGF-b1-sensitive cells. To
explore the role of EBV infection in the development of
EBV-associated gastric carcinoma, we have presented a
model for EBV infection involving the resistance to TGF-
b1-mediated growth inhibition.
MATERIALS AND METHODS
Cell lines and medium
GT38 and GT39 cells were EBV-positive epithelial cell
lines from human gastric tissues (Tajima et al., 1998). The
SC-39 cell line was derived from a human signet ring
ell gastric carcinoma (Yanagihara et al., 1991). The
KN1 and NUGC3 cell lines derived from gastric carci-
omas were obtained from the Japanese Cancer Re-
earch Resources Bank (Tokyo, Japan). Cells were grown
n RPMI 1640 medium supplemented with 10% heat-
nactivated fetal bovine serum (FBS), 100 U/ml penicillin,
nd 100 mg/ml streptomycin at 37°C in a humidified
atmosphere of 5% CO2 in air.
Antibodies and other reagents
TGF-b1 was purchased from Pepro Tech EC Ltd. (Lon-
don, U.K.). Anti-ZEBRA mouse monoclonal Ab was devel-
oped in our laboratory. Anti-early antigen (EA)-D mouse
monoclonal Ab was purchased from DuPont (Wilmington,
DE). Anti-human TGF-b1 Ab was purchased from Gen-
yme/Techne (Cambridge, MA) and from R&D Systems,
nc. (Minneapolis, MN). Biotinylated anti-human TGF-b1
Ab were purchased from R&D Systems. Anti-TGF-b R I
V-22) and anti-TGF-b R II (H-567) Abs were purchased
EBV REACTIVfrom Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
The human cDNA probes for TGF-b1, TGF-b Rs I and II
(
aere kindly provided by Drs. R. Derynk and K. Miyazono,
espectively. cDNAs for junB and PAI-1 were provided by
rs. S. Sharma and D. J. Loskutoff, respectively.
olorimetric assay for cell proliferation
The cell growth was assayed by the incorporation of
TT dye (Chemi-Con Int. Inc., Temecula, CA). Cells were
eeded in 96-well plates (Corning Inc., Corning, NY) at
3 103 cells/100 ml per well for 24 h and then cells were
cultured with various concentrations of TGF-b1 for 72 h.
Ten microliters of MTT solution (5 mg/ml) was added to
each well, and the plates were incubated for 4 h at 37°C.
One hundred microliters of isopropanol with 0.04 N HCl
was added to each well and mixed by repeated pipetting.
Absorbance was measured at a test wavelength of 570
nm and a reference wavelength of 655 nm with a micro-
plate reader (Model 550, Bio-Rad, Richmond, CA).
DNA fragmentation assay
Cells were lysed in an extraction buffer (100 mM NaCl,
10 mM Tris–HCl, pH 8.0, 25 mM EDTA, 0.5% sodium
dodecyl sulfate (SDS) and 0.1 mg/ml proteinase K) at
37°C for 18 h. At the end of the incubation period, the
mixture was treated with an equal volume of phenol-
chloroform-isoamylalchohol (1:1:0.1). DNA was precipi-
tated from the water phase by adding 2.5 vol ethanol and
0.3 M sodium acetate. The precipitated DNA was rinsed
once with 70% ethanol, dried under vacuum, and finally
solubilized into TE buffer (10 mM Tris–HCl, pH 7.6, and 1
mM EDTA) supplemented with RNase I (Promega, Mad-
ison, WI), 0.2 mM sodium acetate, and 50 mM EDTA.
Following incubation at 37°C for 1 h, SDS was added to
the mixture at a final concentration of 0.1% to inactivate
the RNase activity. DNAs were precipitated as described
above and finally solubilized into TE buffer. Five micro-
grams of DNAs were subjected to 2% agarose gel elec-
trophoresis at 100 V for about 1 h. DNA was visualized
with ethidium bromide.
Treatment of TGF-b1
Logarithmically growing cells were suspended to a
inal concentration of 1 3 106 cells/ml with fresh medium.
he cells were cultured for the indicated time with vari-
us concentrations of TGF-b1.
estern blotting
Cells were washed twice with ice-cold phosphate-
uffered saline (PBS) and treated with 10% trichloroace-
ic acid on ice for 15 min, collected in a microcentrifuge
ube, and centrifuged at 15,000 rpm, 0°C for 5 min. The
ellets were lysed in 100 ml lithium dodecylsulfate (LDS)
ample buffer containing 125 mM Tris–HCl (pH 6.8), 2.3%
115BY TGF-b1w/v) LDS, 10% (w/v) glycerol, 5% (v/v) 2-mercaptoethanol,
nd 10 mg/ml bromphenol blue, and boiled for 5 min.
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ferred to a PVDF membrane (Millipore, Bedford, MA).
Blotting of equal amounts of protein to the membrane
was confirmed by Coomassie brilliant blue R-250 dye
staining. After blocking incubation with PBS-Tween 20
containing 5% nonfat dry milk powder for 2 h at RT, the
membranes were incubated with either anti-ZEBRA or
anti-EA-D overnight at 4°C. Following primary antibody
incubation, the membranes were incubated with anti-
mouse antibody (New England Biolabs, Beverly, MA)
conjugated to alkaline phosphatase. The membranes
were further processed using the Western–light chemi-
luminescent detection system (Tropix, Bedford, MA).
Northern blotting
Total RNA was prepared by the guanidium thiocyanate
method per instructions (Isogen, Wako, Osaka, Japan)
and Northern blots were performed as previously de-
scribed (Gao et al., 1999). Briefly, each RNA sample was
enatured for 5 min at 65°C in 50% formamide and 2.2 M
ormaldehyde, and then electrophoretically separated in
% agarose gels. The RNA was then transferred onto
ybond-N filter paper (Amersham, Tokyo, Japan) and
rehybridization was performed for 24 h at 42°C in 50%
ormaldehyde, 53 SSC, 2.53 Denhardt’s solution, 0.1%
SDS, and 300 mg salmon sperm DNA/ml. The mem-
branes were hybridized 24 h at 42°C with random
primer-labeled cDNA probes, respectively. After hybrid-
ization, the membranes were washed twice at 65°C in
13 SSC, 0.1% SDS for 10 min and were exposed to Kodak
XAR film. Equal loadings of RNA were confirmed by
hybridization with glyceraldehyde-3-phosphate-dehydro-
genase (GAPDH) cDNA probe.
Assay of TGF-b1 by ELISA
TGF-b1 was quantified by the fluorometric sandwich
ELISA described previously (Sakaguchi et al., 1989). F96
Maxisorp Nunc-Immuno Plate (Nalge Nunc International,
Dansk Kraftemballage, Denmark) was coated with 4
mg/ml of anti-human TGF-b1 Ab (R&D Systems) in 0.05 M
carbonate-bicarbonate buffer (pH 9.5) for 3 h at 37°C.
The plate was emptied and then coated with 1% BSA–
PBS at 37°C for 1 h. After washing, supernatants and
several concentrations of TGF-b1 in 1% BSA–PBS Tween
0 were added to the wells, and the plate was incubated
vernight at 4°C. The plate was washed, and 100 ng/ml
iotinylated anti-human TGF-b1 Ab (R&D Systems) was
dded as a detector antibody. The plate was incubated
or 1 h at room temperature. After washing, b-D-galacto-
idase-conjugated streptavidin (Gibco-BRL, Gaithers-
urg, MD) diluted 10,000 was added. The plate was
ncubated for 1 h at room temperature. After washing, 0.1
M 4-metylumbelliferyl-b-D-galactoside (Sigma, Stein-
116 FUKUheim, Germany) in 0.1 M NaCl, 1 mM MgCl2, 0.1% BSA, 10
mM Na-phosphate, and 0.02% NaN3 was added to eachwell. The plate was incubated for 2 h at 37°C. The
enzyme reaction was stopped with 0.1 M glycine–NaOH
(pH 10.2), and the fluorescence intensity was read as
fluorescence units on a microplate fluorescence reader
(Cyto Fluor, PerSpective Biosystems, Osaka, Japan).
Assay of biological active TGF-b1
Cells were seeded in complete medium at 1 3 106
cells/ml and incubated for 24 h. The supernatants were
collected from cultures after centrifugation, filtered
through a 0.45-mm filter, and used immediately for the
growth inhibition test on HSC-39 or GT38 cells. Cells
were seeded in 96-well plates at a density of 5 3 103
cells/well with supernatant from GT38 or GT39 cells.
After 72 h, cell growth was measured by MTT assay.
Neutralization test of TGF-b1 with anti-TGF-b1
antibody
Neutralizing activity of TGF-b1 with anti-human
TGF-b1 antibody was measured as abrogation of growth
inhibition to HSC-39 cells by TGF-b1 in the supernatants
from GT38 or GT39 cells. Various concentrations of the
anti-human TGF-b1 antibody were mixed with the super-
natants for 10 min at 37°C, which were then added to
HSC-39 cells. The cells were cultured for 72 h at 37°C
and cell growth was measured using the MTT assay.
Fluorescence-activated cell sorting analysis for
apoptosis
Cells were washed in cold PBS, and single cell sus-
pensions were fixed with 70% ethanol at 4°C for 1 h, and
then incubated with PBS solution containing 50 mg/ml
Nase A at 37°C for 20 min. DNA content of the cells
as measured after staining with 50 mg/ml propidium
odide by flow cytometry using an EPICS XL flow cytom-
ter (Coulter Corp., Miami, FL). Cells containing less
NA than those in G0/G1 phase represent apoptotic
ells.
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